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Abstract
Motivation: Uncovering the genomic causes of cancer, known as cancer driver genes, is a fundamental
task in biomedical research. Cancer driver genes drive the development and progression of cancer, thus
identifying cancer driver genes and their regulatory mechanism is crucial to the design of cancer treatment
and intervention. Many computational methods, which take the advantages of computer science and
data science, have been developed to utilise multiple types of genomic data to reveal cancer drivers and
their regulatory mechanism behind cancer development and progression. Due to the complexity of the
mechanistic insight of cancer genes in driving cancer and the fast development of the field, it is necessary
to have a comprehensive review about the current computational methods for discovering different types
of cancer drivers.
Results: We survey computational methods for identifying cancer drivers from genomic data. We
categorise the methods into three groups, methods for single driver identification, methods for driver
module identification, and methods for identifying personalised cancer drivers. We also conduct a case
study to compare the performance of the current methods. We further analyse the advantages and
limitations of the current methods, and discuss the challenges and future directions of the topic. In
addition, we investigate the resources for discovering and validating cancer drivers in order to provide a
one-stop reference of the tools to facilitate cancer driver discovery. The ultimate goal of the paper is to
help those interested in the topic to establish a solid background to carry out further research in the field.
Keywords: cancer driver, cancer driver discovery, computational method
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1 Introduction
Identifying cancer driver genes (cancer drivers for short) is vital since these
genes play a significant role in the development of cancer. Understanding
cancer drivers and their regulatory mechanism is crucial to the design of
effective cancer treatments.
Classical methods of identifying cancer driver genes are based on
detecting the mutations in the DNA sequences of coding genes in wet-
lab experiments. There are many mutation types in the genome such as
single-nucleotide variants (SNVs), structural variants (SVs), insertions and
deletions (indels), and copy number aberrations (CNAs) (Dimitrakopoulos
and Beerenwinkel, 2017). These mutations may cause normal cells to
transform to tumour cells, resulting in the development of cancer. For
example, it has been confirmed that mutations in genes VHL and MET
cause kidney cancer (Linehan et al., 2010) and mutations in genes AKT1
and BRCA1 are related to breast cancer (Stephens et al., 2012). However,
many mutated genes are not driver genes and may not regulate the
progression of cancer. The reason is that not all mutations in the genome
contribute to cancer development. Mutations which play a significant
role in cancer progression are called driver mutations while mutations
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2 Pham et al.
which do not have any impact on cancer development are called passenger
mutations (Leiserson et al., 2015; Vandin, 2017). Genes which bear
cancer driver mutations are considered as cancer drivers (Tokheim et al.,
2016). Nevertheless, some cancer drivers may not contain mutations. For
example, genes which may not contain mutations but regulate targets to
develop cancer are also considered as cancer driver, e.g. the overexpression
of KDM5C decreases p54 expression to enhance the proliferation and
invasion of gastric cancer cells and KDM5C is considered as a cancer
driver (Xu et al., 2017a). The illustration of cancer drivers and genes with
mutations is shown in Figure 1.
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Fig. 1. Cancer drivers and genes with mutations. Genes with driver mutations are cancer
drivers. Some genes which do not contain mutations but regulate driver mutations to develop
cancer are also considered as cancer drivers.
Given the complexity of the regulation by cancer drivers and the
large number of genes, over ten thousand, detecting cancer driver genes
is challenging with the wet-lab experiments and many computational
methods utilising multiple types of genomic data have been developed
to reveal cancer drivers and their regulatory mechanism behind the cancer
development (Fattore et al., 2016; Gasparini et al., 2015; Papaemmanuil
et al., 2016; Rassenti et al., 2017). Cancer driver discovery methods are
increasingly popular recently because of the fast development of computer
science and significant revolution of DNA sequencing techniques. Taking
these advantages, numerous methods have been proposed to detect
cancer driver genes. For example, MutSigCV (Lawrence et al., 2013)
investigates the significance of mutations in genes to predict cancer
drivers, OncodriveFM (Gonzalez-Perez and Lopez-Bigas, 2012) and
OncodriveCLUST (Tamborero et al., 2013) evaluate the functional
influence and clustering of gene mutations respectively, DriverNet
(Bashashati et al., 2012), MEMo (Ciriello et al., 2012), and CBNA (Pham
et al., 2019) examine the role of genes in gene regulatory networks. Due to
the large number of the current computational methods for cancer driver
discovery, it may take the huge amount of effort for people to find a
good resource to know the state-of-the-art methods, and thus a review
is necessary and helpful.
There have been previous works (Dimitrakopoulos and Beerenwinkel,
2017) reviewing the computational methods for identifying single cancer
drivers at the population level. However, it is important to gain mechanistic
insight into how cancer drivers work together in driving cancer. Besides,
cancer drivers of each patient may be different from others since cancer is a
heterogeneous disease, each patient has a different genome and the disease
of each patient may be driven by different cancer driver genes. Thus, we
also need to consider cancer driver modules and personalised cancer drivers
(i.e. cancer drivers for a specific patient). In addition, there are numerous
new cancer driver identification methods which have been developed since
then. Therefore, it is required to have a more comprehensive review about
the current computational methods for identifying cancer drivers.
In this paper, we survey computational methods for discovering both
single cancer drivers and cancer driver modules at the population level and
the individual level as well. We then analyse the advantages/disadvantages
of the current methods and identify challenges of the field. To facilitate the
development of new computational methods for cancer driver detection,
we survey resources which can be used as tools in conducting cancer driver
research and validating predicted cancer drivers. In addition, with the case
study conducted to compare the performance of the current methods in
this paper, we believe it will be useful for researchers, who are interested
or work in the field, to develop their new methods.
The paper is structured as follows. In Section 2, we review
computational methods for identifying single and cancer driver modules
from genomic data, including cancer drivers for both the population and
individuals. We summarise the current available sources which can be used
for conducting cancer driver researches as well as validating the results in
Section 3. In Section 4, we carry out a case study. Finally, we analyse the
current methods to identify their advantages and limitations then discuss
future directions and challenges of the field in Section 5.
2 Cancer driver discovery methods
The current computational methods use a wide range of genomic data
types, including mutations, gene expression, pathways, etc. to discover
different types of cancer drivers. Thus, we categorise the methods into
various categories and sub-categories. The diagram of the categorisation
is shown in Figure 2 and the summary of the methods is presented in
Table 1.
Cancer
driver module
identification
Cancer driver
discovery methods
Single cancer driver
identification
Personalised cancer
driver
identification
Mutation-based
methods
Network-based
methods
Mutation significance Functional impact ofmutations Location of mutations Others
Mutual exclusivity Others
Fig. 2. Categorisation of cancer driver discovery methods. The methods are categorised
in three groups: Single cancer driver identification, Cancer driver module identification,
and Personalised cancer driver identification. Single cancer driver identification includes
two sub-groups: Mutation-based methods and Network-based methods. Mutation-based
methods discover cancer drivers using mutation significance, functional impact of
mutations, location of mutations, etc. Most cancer driver module identification methods
use the mutual exclusivity of mutations to identify modules of cancer drivers.
In the categorisation, we differentiate single cancer drivers from
modules of cancer drivers since there is evidence showing that some genes
work in concert to influence different biological processes (e.g. EMT)
(Cursons et al., 2017) and in some biological processes, the regulation
of single genes might not have significant impacts but the regulation of
groups of genes does. Furthermore, as cancer is a heterogeneous disease,
each patient may have a different morphology and clinical outcome. For
instance, two patients, who have the same cancer type and receive the
same treatment, may experience different outcomes. The reason is that
the genome of each patient is different and each patient’s disease may
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Cancer Driver Discovery 3
Table 1. Summary of methods for identifying cancer drivers
Category Sub-category Method Description
Single cancer driver
identification
Mutation-based methods
(Using mutation significance)
MutSigCV (Lawrence et al., 2013) Assesses the significance of mutations in DNA sequencing in order to discover
cancer driver genes.
Mutation-based methods
(Using functional impact
of mutations)
OncodriveFM (Gonzalez-Perez and Lopez-Bigas, 2012) Uses the functional impact of mutations of genes to detect cancer drivers with the
hypothesis that any bias of variations with a significantly functional impact in genes
can be used to identify candidate driver genes.
OncodriveFML (Mularoni et al., 2016) Uses the functional impact of gene mutations to reveal both coding and non-coding
cancer drivers.
DriverML (Han et al., 2019) Uses the functional impact of mutations to unravel cancer drivers through a
supervised machine learning approach.
Mutation-based methods
(Using location of mutations)
ActiveDriver (Reimand and Bader, 2013) Looks at the enrichment of mutations in externally defined regions to uncover cancer
driver genes.
OncodriveCLUST (Tamborero et al., 2013) Detects cancer genes with a large bias in clustering mutations based on the idea
that gain-of-function mutations usually cluster in particular protein sections and these
mutations contribute to the development of cancer cells.
Mutation-based methods
(Others: Combining with
gene expression, pathways)
IntOGen-mutations (Gonzalez-Perez et al., 2013) Uses somatic mutations, gene expression, and tumour pathways to identify cancer
drivers for various tumour types by combining OncodriveFM (Gonzalez-Perez and Lopez-Bigas, 2012) and
OncodriveCLUST (Tamborero et al., 2013).
PathScan (Wendl et al., 2011) Combines genomic mutations with the information of genes in known pathways to
uncover cancer driver genes.
Sakoparnig et al. (Sakoparnig et al., 2015) Introduces a computational method to detect genomic alterations with low
occurrence frequencies based on mutation timing.
CONEXIC (Akavia et al., 2010) Applies a score-guided search to detect combinations of modulators which reflect
the expression of a gene module in a set of tumour samples then it identifies those
which have the highest score in amplified or deleted regions.
ncDriver (Hornshoj et al., 2018) Screens non-coding mutations with conservations and cancer specificity to reveal
non-coding cancer drivers.
Network-based methods Vinayagam et al. (Vinayagam et al., 2016) Applies controllability analysis on the directed network of human protein-protein
interaction to identify disease genes.
CBNA (Pham et al., 2019) Identifies coding and miRNA cancer drivers by analysing the controllability of the
miRNA-TF-mRNA network and mutation data.
DriverNet (Bashashati et al., 2012) Uncovers cancer drivers by evaluating the influence of mutations on transcriptional
networks in cancer.
Cancer driver module
identification
Using mutual exclusivity
of mutations
CoMEt (Leiserson et al., 2015) Identifies cancer genes by using the exact statistical test to test mutual exclusivity
of genomic events and applies techniques to do simultaneous analysis for mutually
exclusive alterations.
WeSME (Kim et al., 2017) Discovers cancer drivers by evaluating the mutual exclusivity of mutations of gene
pairs.
MEMo (Ciriello et al., 2012) Analyses mutual exclusivity of mutated genes in subnetworks to identify mutual
exclusivity modules in cancer.
Others: Using mutations,
gene expression, gene network
iMCMC (Zhang et al., 2013) Uses the cancer genomic data including mutations, CNAs, and gene expression from
cancer patients to identify mutated core modules in cancer.
NetBox (Cerami et al., 2010) Uses biological networks to assess network modules statistically and identify core
pathways in GBM.
TieDIE (Paull et al., 2013) Applies network diffusion to discover the relationship of genomic events and changes
in cancer subtypes.
Hamilton et al. (Hamilton et al., 2013) Uses the pan-cancer dataset of TCGA and the miRNA target data of AGO-CLIP to
detect a pan-cancer oncogenic miRNA superfamily with a central core seed motif.
Personalised cancer driver
identification
DawnRank (Hou and Ma, 2014) A ranking framework which applies PageRank to evaluate the impact of genes in
an interaction network to detect cancer drivers.
SCS (Guo et al., 2018) Detects the minimal set of mutated genes controlling the maximal differentially
expressed genes as cancer drivers.
PNC (Guo et al., 2019) Identifies cancer drivers as the minimum gene set which covers all the edges based on
a bipartite graph.
be driven by different driver genes, leading to a strong need to study
cancer driver genes specific to an individual patient. Thus, we categorise
the current computational methods for cancer driver discovery into three
groups, including methods to identify single cancer drivers, methods to
identify cancer driver modules, and methods to discover personalised
cancer drivers (i.e. cancer drivers for a specific patient). In addition,
based on the key techniques used in the methods, we divide single cancer
driver identification methods into two sub-groups, including mutation-
based methods and network-based methods. Mutation-based methods
use different characteristics of mutations such as mutation significance,
functional impact of mutations, location of mutations to discover cancer
drivers while network-based methods evaluate the role of genes in
biological networks to predict cancer drivers. Most of cancer driver module
identification methods use the mutual exclusivity of mutations to identify
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modules of cancer drivers. We will discuss the detail of the methods in the
following sections.
2.1 Single cancer driver identification
Most current methods identify single cancer drivers at the population
level. In general, they can be grouped in mutation-based methods and
network-based methods. Mutation-based methods use the characteristics
of mutations (e.g. the significance of mutations in genes, the functional
impacts of mutations, the recurrence of mutations in genes, etc.) to identify
cancer driver genes while network-based methods use gene networks to
assess the role of genes then combine with the mutation information to
predict cancer drivers. The general idea of the network-based methods is
illustrated in Figure 3.
Evaluate genes
Combine
Networks
Mutations Gene roles
Cancer
drivers 
Fig. 3.Network-based methods. Network-based methods evaluate the role of genes in gene
regulatory networks by using different techniques and combine with the mutations of genes
to predict cancer drivers.
2.1.1 Mutation-based methods
Mutation-based methods use the characteristics of mutations in genes to
discover cancer driver genes. Based on the characteristics of mutations
used in the methods, we divide them into four sub-groups, including using
the significance of mutations in genes, using the functional impacts of
mutations, using the recurrence of mutations, and others. Other methods
combine the mutation information of genes with gene expression and
tumour pathways to detect cancer drivers. The details of methods in the
four sub-groups are discussed as below.
A. Using the significance of mutations in genes
MutSigCV (Lawrence et al., 2013) is a method to discover cancer
drivers by assessing the significance of mutations in genes. Cancer
drivers predicted by MutSigCV are mutated more frequently than expected
by chance based on inferred background mutation processes. However,
MutSigCV has a limitation since although some genes have a high degree of
mutations, these mutations are passenger mutations and do not contribute
to the cancer development.
B. Using the functional impacts of mutations
OncodriveFM (Gonzalez-Perez and Lopez-Bigas, 2012) uses the
functional impact of genomic mutations to detect cancer drivers instead
of evaluating the significance of mutations in genes like MutSigCV.
OncodriveFM hypothesises that any bias of variations (i.e. mutations)
in genes with a significantly functional impact may be an indicator for
identifying candidate driver genes. The significant point of this method is
that instead of assessing how many mutations a gene has, it evaluates how
biased mutations with highly functional impacts are. Thus, it can detect
driver genes having mutations with low recurrence but their mutations play
a significant role in the cancer development.
Similar to OncodriveFM, OncodriveFML (Mularoni et al., 2016)
also uses the functional impact of mutations to discover cancer
drivers. However, while OncodriveFM only uses coding gene mutations,
OncodriveFML is designed to analyse both coding and non-coding
mutations. The OncodriveFML framework is then applied to 19 tumour
datasets and uncovers well-known coding drivers like TP53, KEAP1,
ARID2, and RUNX1 with high functional impacts. It also identifies non-
coding drivers such as MALAT1 and MIAT. In particular, MALAT1 is a
lncRNA which has been proved to be involved in lung adenocarcinomas
and MIAT is a non-protein-coding transcript related to myocardial
infarction.
Another method assessing the functional impact of gene mutations
to unravel cancer driver is DriverML (Han et al., 2019). Different
from OncodriveFM and OncodriveFML, DriverML assumes that the
functional impact of mutations is affected by mutation types. Thus,
it proposes a method to detect cancer drivers by scoring functional
influences of alterations based on mutation types. The method uses various
properties to weight the impact of mutation types and it obtains optimised
weight parameters by using a supervised machine learning approach with
pan-cancer training data.
C. Using the recurrence of mutations in genes
Instead of using the functional impact of mutations like OncodriveFM,
OncodriveFML, and DriverML, other methods identify cancer drivers
based on the location of mutations such as ActiveDriver (Reimand
and Bader, 2013) and OncodriveCLUST (Tamborero et al., 2013).
ActiveDriver discovers cancer driver genes by detecting the enrichment
of somatic mutations in post-translationally modified sites, including
phosphorylation, acetylation, and ubiquitination sites. OncodriveCLUST
is based on the fact that gain-of-function mutations usually cluster
in particular protein sections and these mutations contribute to the
development of cancer cells. Thus, it detects cancer genes with a large bias
in clustering mutations. The method is applied to the database of Catalogue
of Somatic Mutations in Cancer (COSMIC) (Forbes et al., 2010) and then
the result is validated with the Cancer Gene Census (CGC) (Futreal et al.,
2004). As this method bases on the mutation clustering, it cannot identify
cancer drivers whose mutations are distributed across the sequence. In
addition, to have a good result, it requires a large number of observed
mutations. Thus, this method should be used to complement results of
other methods in detecting cancer drivers.
D. Others: Combining with gene expression, pathways, etc.
The platform IntOGen-mutations (Gonzalez-Perez et al., 2013) is
developed based on OncodriveFM and OncodriveCLUST to discover
cancer drivers for various tumour types. This platform uses somatic
mutations, gene expression, and tumour pathways as the input
parameters. It takes the advantages of both methods using the functional
impact of mutations and methods using the location of mutations
by applying OncodriveFM to identify driver genes which are biased
significantly toward mutations with high functional impacts and applying
OncodriveCLUST to detect driver genes which have mutations highly
concentrating in specific regions of proteins.
Also using mutational infomation in detecting cancer genes, PathScan
(Wendl et al., 2011) combines mutations with the information of genes in
known pathways. PathScan tests the scenario in which pathway mutations
contribute to the development of tumour. In addition, other methods
combine mutations with existing knowledge of gene function or network
structure, or finding mutually exclusive mutations, etc. For instance,
Sakoparnig et al. (Sakoparnig et al., 2015) introduce a computational
method to detect genomic alterations with low occurrence frequencies
based on mutation timing.
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Especially, some methods combine a wide range of data types in order
to identify cancer drivers more effectively. For example, in (Akavia et al.,
2010), the authors develop a computational framework which uses CNVs
and gene expression as the inputs to uncover cancer drivers. The framework
is named COpy Number and EXpression In Cancer (CONEXIC). It applies
a score-guided search to detect combinations of modulators which reflect
the expression of a gene module in a set of tumour samples. Then it
identifies those having the highest score in amplified or deleted regions
on chromosome. The authors hypothesise that in case the expression of
gene A and its copy number are related, the copy number variation likely
results in changes in expression of gene A and there is a high probability
that A is a driver candidate and it regulates other genes. The authors apply
this framework to the dataset of melanoma and detect exactly its known
cancer drivers.
ncDriver (Hornshoj et al., 2018) identifies non-coding cancer drivers
with a two-stage procedure. The first stage is mutational recurrence test
which uses mutations (including indels and SNVs) and genomic elements
as the inputs to detect elements with mutational recurrence. The second
stage is to assess whether mutations of each element have a significant
cancer-specific distribution and significant bias for highly conserved
positions of each element, then it finds out if the conservation level of
mutations is significantly large comparing to the overall conservation
distribution. This procedure is applied to the pan-cancer whole-genome
dataset to identify cancer drivers and significant non-coding drivers
identified by the method are MIR142 lncRNA and XRNU5A-1 sncRNA.
E. Analysis
Although all the methods above base on mutation data to identify
cancer drivers, each has a different approach. MutSigCV evaluates the
significance of mutations in genes to detect cancer drivers. However,
some genes are mutated significantly but most of their mutations are
passenger mutations, which do not progress cancer. Thus, these genes are
not cancer driver genes. To eliminate passenger mutations, ActiveDriver
and OncodriveCLUST consider the location of mutations. Although these
methods can reduce the false positives in predicting driver mutations, they
may overlook cancer drivers with mutations distributing across the protein
since they only evaluate mutations which are concentrated in particular
protein sections. Instead of using the location of mutations, other methods
use different strategies. For instance, OncodriveFM, OncodriveFML, and
DriverML utilise the functional impact of genomic mutations to evaluate
the importance of mutated genes to discover cancer drivers. Sakoparnig et
al. (Sakoparnig et al., 2015) bases on the timing of mutations, PathScan
combines with the pathway data, and CONEXIC combines with the gene
expression data. There are also methods which use an integrated approach
such as IntOGen-mutations, which considers both the functional impact
of mutations and their clustering as well. Furthermore, since mutations
in both coding regions and non-coding regions play a significant role in
cancer development, cancer drivers can be coding or non-coding elements.
Some methods like OncodriveFML and ncDriver are developed to detect
non-coding cancer drivers.
As these methods evaluate different aspects of mutations to identify
cancer drivers, they can detect several validated cancer drivers. The novel
cancer drivers identified by these methods are potential and they can be
used in wet-lab experiments to confirm their role in cancer progression.
However, although these methods can be easily applied to different
mutation datasets, mutation databases are incomplete and the applications
of these methods are limited.
2.1.2 Network-based methods
In general, network-based methods evaluate the role of genes in biological
networks and then combine with the muttaion information of genes to
predict cancer drivers. There are three methods in this group, including
Vinayagam et al. (Vinayagam et al., 2016), CBNA (Pham et al., 2019),
and DriverNet (Bashashati et al., 2012). The details of these methods are
discussed as below.
A. The details of methods
Vinayagam et al. (Vinayagam et al., 2016) applies controllability
analysis on the directed network, i.e., the network with directed edges, of
human protein-protein interaction (PPI). The input network includes nodes
which are proteins and edges which are interactions between proteins.
The controllability analysis categorises nodes into the three types which
are "indispensable", "dispensable", or "neutral" based on their impact on
minimum driver node set (MDS), i.e., the minimum node set driving the
whole network. Indispensable nodes are nodes which make the number
of MDS increased when the nodes are removed from the network, while
dispensable nodes make the number of MDS decreased. The removal of
neutral nodes from the network has no effect on the number of driver
nodes. Then the study analyses the controllability of perturbated network
to identify sensitive indispensable nodes, i.e., indispensable nodes in
the original network but not in the perturbated network. These sensitive
indispensable nodes are the candidate cancer drivers.
Also inspired by the network controllability, CBNA (Pham et al.,
2019) analyses the controllability of a gene regulatory network to discover
cancer drivers. However, the network built by CBNA is a miRNA-TF-
mRNA network which consists of microRNAs (miRNAs), Transcription
Factors (TFs), and mRNAs. Since this network is constructed from
the expression data of miRNAs/mRNAs of cancer patients and the
existing gene interaction databases such as PPI (Vinayagam et al., 2011),
miRTarBase (Chou et al., 2016), and TransmiR (Wang et al., 2010), it is
more reliable and specific to a cancer type. In addition, different from the
method of Vinayagam et al. (Vinayagam et al., 2016), CBNA analyses
the network controllability to indicate critical nodes of the network, i.e.
nodes increase the number of the minimum node set controlling the whole
network if they are removed from the network, then combining with the
mutation data to identify cancer drivers. As CBNA uses the miRNA-TF-
mRNA network, it can identify both coding and miRNA driver genes.
Furthermore, it can also be used to discover drivers for a cancer type or
cancer subtype.
Instead of evaluating the controllability of a subset of nodes of a gene
network like Vinayagam et al. (Vinayagam et al., 2016) and CBNA (Pham
et al., 2019), DriverNet (Bashashati et al., 2012) considers the influence
of mutated genes on other genes in a network. DriverNet integrates
different data types, including genome data (i.e. non-synonym SVNs,
indels, and copy number variation), influence graph of biological pathway
information, and gene expression. It constructs a bipartite graph of genes
to detect the effect of mutated genes on genes which have an outlying
expression. The putative drivers are mutated genes which impact on a
high number of outlying-expression genes in several patients. The method
is applied to four cancer datasets, including glioblastoma, breast, triple
negative breast, and serous ovarian, and it reveals various candidate cancer
drivers related to transcriptional networks.
B. Analysis
The three methods above use biological networks to predict single
cancer drivers, other methods using networks to discover cancer driver
modules or personalised cancer drivers are discussed in Section 2.2 and 2.3
respectively. In general, network-based methods evaluate the role of genes
in the whole networks to predict cancer drivers. Various techniques are used
to analyse the networks such as network controllability in Vinayagam et
al. and CBNA or the influence of genes in DriverNet. These methods can
elucidate molecular mechanisms in cancer development at the network
level, but they need large datasets to produce reliable results. In addition,
the networks used in some methods (i.e. Vinayagam et al. and DriverNet)
are not specific to any cancer type, thus they may miss some important
information which is specific to a cancer type. Another limitation of
i
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network-based methods like DriverNet is predicting genes which affect
other genes’ expression as cancer drivers, because some cancer drivers
may not alter the expression of other genes or other genes accidentally
change other genes’ expression although they are not cancer drivers.
2.2 Cancer driver module identification
Recently, several methods have been developed to discover cancer drivers
in modules. Most of the methods identifying cancer driver modules use
mutual exclusivity of mutations. Thus, we divide methods for identifying
cancer driver modules into two sub-groups: using mutual exclusivity of
mutations and others. Other methods use mutations, gene expression, gene
network, etc. to detect cancer driver modules. The details of methods in
the two sub-groups are discussed as below.
A. Using mutual exclusivity of mutations
CoMEt (the Combinations of Mutually Exclusive Alterations)
(Leiserson et al., 2015) uses mutual exclusivity technique to detect
cancer driver modules. Because different cancer patients have different
combinations of genomic alterations which develop the disease, CoMEt
detects combinations of alterations (i.e. modules of mutated genes) in
the same pathway, which are mutual exclusive across samples. The
method uses the exact statistical test to test mutual exclusivity and it does
simultaneous analysis for mutually exclusive alterations specific to cancer
subtypes. The advantage of this method is that it has a low computational
complexity. Similarly, WeSME (Kim et al., 2017) also assesses the mutual
exclusivity of mutations of genes to detect cancer drivers. However, instead
of evaluating genes in the same pathway, WeSME only considers gene pairs
and the gene pairs whose mutations have a significantly mutual exclusivity
are considered as modular candidate cancer drivers.
MEMo (Mutual Exclusivity Modules) (Ciriello et al., 2012) applies
mutual exclusivity technique in biological networks to identify oncogenic
network modules. According to (Ciriello et al., 2012), although individual
tumours of the same cancer type may have different genomic alterations,
these alterations just happen in a restricted number of pathways. In
addition, alterations in the same pathway are not likely to exist in the
same patient. Based on these, MEMo does correlation analysis and applies
statistical tests to detect network modules based on three criteria: (1) genes
in a network module are altered across the sample; (2) member genes tend
to join into the same biological process; (3) alterations in modules are
mutually exclusive. The method is applied to the glioblastoma multiforme
(GBM) dataset and detects successfully known network modules, i.e.,
groups of cancer drivers, in GBM.
B. Others: Using mutations, gene expression, gene network, etc.
iMCMC (an approach to identify Mutated Core Modules in Cancer)
(Zhang et al., 2013) is developed to uncover groups of genes driving cancer
using the cancer genomic data from cancer patients. The method uses
somatic mutation, CNV, and gene expression to build a gene network.
Then, it identifies coherent subnetworks (modules) from the network
through an optimisation model by selecting vertices and edges with high
weights. Finally, the significance of subnetworks is assessed by performing
a random test and the mutual exclusivity of subnetworks is tested by
adopting Markov chain Monte Carlo permutation strategy. The method is
applied to the GBM and the ovarian carcinoma (OV) datasets from TCGA.
Many discovered core modules are related to known pathways and most
of the identified genes are cancer driver genes which are already reported
relating to cancer pathogenesis in other research.
NetBox (Cerami et al., 2010) uses biological networks in studying
drivers for GBM. It introduces a network-based method to detect oncogenic
processes and cancer driver genes. The hypothesis of the approach
is that biological networks include multiple functional modules, and
tumours target specific functional modules. The method analyses sequence
mutations, CNVs, an interaction network including both PPIs and
signalling pathways to identify and assess network modules statistically.
Another method to identify cancer driver modules is TieDIE (Tied
Diffusion Through Interacting Events) (Paull et al., 2013). TieDIE applies
network diffusion to discover the relationship of genomic events and
changes in cancer subtypes. The approach collects a subnetwork of PPIs,
interactions of genomic perturbations, predicted transcription factor-to-
target connections, and transcriptomic states from literature. The method
is applied to the breast adenocarcinoma (BRCA) dataset of TCGA and it
detects signalling pathways and interlinking genes corresponding to cancer
signalling.
The methods above identify coding cancer driver modules. However,
because non-coding RNAs (e.g. miRNAs) can modulate tumorigenesis by
promoting or suppressing specific genes and various cancer types have
overlaps in oncogenic pathways, a group of miRNAs which drives or
suppresses tumorigenesis in different tumour types may exist. Hamilton
et al. (Hamilton et al., 2013) use the pan-cancer dataset of TCGA and
the miRNA target data of Argonaute Crosslinking Immunoprecipitation
(AGO-CLIP) (Chi et al., 2009; Hafner et al., 2010, 2012) to detect pan-
cancer miRNA drivers. The idea is that the set of cancer miRNA drivers
will modulate tumorigenesis and share a central core seed motif. The result
shows that an oncogenic miRNA superfamily, which includes miR-17,
miR-18, miR-19, miR-93, miR-130, miR-210, and miR-455, coregulates
tumour suppressors through a GUGC core motif.
C. Analysis
As can be seen from the methods above, most of the methods use
mutual exclusivity of mutations to identify cancer driver modules. With this
technique, the mutation from only one member in an identified module is
enough to trigger cancer progression (Kim et al., 2017). Thus, the identified
drivers in a module may not work together to regulate their targets to drive
cancer. However, as discussed above, genes should collaborate to increase
their influence on target genes to progress cancer. Therefore, it is necessary
to develop novel methods to discover cancer driver groups whose members
work in concert to initialise and develop cancer.
2.3 Personalised cancer driver identification
The methods discussed in Section 2.1 and 2.2 discover cancer drivers at
the population level. Since different patients possess different genomes
and their diseases might be driven by different driver genes, it is necessary
to investigate cancer drivers which are specific to an individual patient
(i.e. personalised cancer drivers). There are three methods in this group,
including DawnRank (Hou and Ma, 2014), SCS (Guo et al., 2018), and
PNC (Guo et al., 2019). All of them base on gene regulatory networks
to predict personalised cancer drivers. The details of these methods are
discussed as below.
A. The details of methods
A representative of methods for identifying personalised cancer drivers
is DawnRank (Hou and Ma, 2014). In general, the idea of the method is
that mutations in genes which have higher connectivity in an interaction
network are more impactful. DawnRank uses the information of gene
expression and gene network as the inputs. In particular, it is a ranking
framework which applies PageRank (Brin and Page, 1998; Page et al.,
1998) to evaluate the impact of genes on the gene network. The impact is
presented in terms of network connectivity and the number of downstream
genes expressed differentially. The higher the rank of a gene is, the more
downstream genes it has effects on in the gene network. Ranks of genes are
then combined with somatic alteration data like copy number variations to
detect driver alterations. Although DawnRank bases on the same gene
regulatory network for all patients, it assesses the impact of genes in
each patient using the patient’s gene expression data to detect personalised
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Table 2. Summary of resources for identifying cancer drivers and validating the predicted results
Category Resource Website Description
For identifying
cancer drivers
TCGA (Institute, 2018) https://www.cancer.gov/about-nci/organization/
ccg/research/structural-genomics/tcga
Profiles human tumours to discover molecular aberrations in
DNA, XRNA, protein, and epigenetic levels.
ICGC (Zhang et al., 2011) https://icgc.org/ A data portal of cancer gemomics of 50 cancer types.
cBioPortal (Gao et al., 2013) http://www.cbioportal.org/ A web interface for accessing cancer genomic data and
analysing the data.
Cancer3D (Porta-Pardo et al., 2015) http://cancer3d.org/search Contains mutations of more than 14,700 proteins and they are
mapped to over 24,300 proteins of the Protein Data Bank (Rose et al., 2013).
CCLE (Barretina et al., 2012) https://portals.broadinstitute.org/ccle Includes SNVs, CNAs, and gene expression.
COSMIC (Forbes et al., 2015) https://cancer.sanger.ac.uk/cosmic Contains cancer mutations, including manually curated expert
data and data from sequencing projects.
For validating
predicted results
CGC (Futreal et al., 2004) https://cancer.sanger.ac.uk/census Provides a list of cancer genes, which has been well
established for cancer development.
AGCOH (Huret et al., 2000) http://atlasgeneticsoncology.org/ Contains about 1,500 cancer genes merged from numerous
collaborative projects.
NCG An et al. (2016) http://ncg.kcl.ac.uk/ Comprises more than 500 known cancer genes and over 1,000
candidate cancer genes.
DGIdb (Griffith et al., 2013) http://www.dgidb.org/ Includes cancer drivers and drug-gene interactions.
OncomiR (Wong et al., 2018) http://www.oncomir.org/ A web interface for investigating miRNA dysregulation in
cancer.
cancer drivers. The algorithm has been applied to TCGA datasets and it
shows an effectiveness in detecting cancer drivers.
To assess the impact of genes in each patient, DawnRank uses the gene
expression data of each patient, but it bases on the same gene regulatory
network of all patients. As a result, it may miss important information
of gene regulation of each patient. Thus, to detect personalised cancer
drivers, SCS (Guo et al., 2018) builds a gene regulatory network for each
patient from the patient’s gene expression data and its neighbour’s gene
expression data (i.e. the corresponding normal sample’s gene expression
data). SCS detects cancer driver genes as the minimal set of mutated genes
which impacts on the maximal differentially expressed genes. Like SCS,
PNC (Guo et al., 2019) also uses the gene expression data of a patient and
its neighbour to construct personalised networks. Nevertheless, PNC only
selects edges which are different between the tumour and normal state. It
then converts the gene regulatory network to a bipartite graph in which,
nodes on the top represent genes and nodes on the bottom represent edges.
PNC predicts cancer driver genes as the minimum gene set on the top of
the bipartite graph which covers all the edges on the bottom.
B. Analysis
Although these methods can discover personalised cancer drivers, they
still have some limitations. DawnRank bases on the same gene network
of all patients. It ignores the network information specific to an individual
patient, leading to false positives in its results. On the other hand, SCS
and PNC use the genetic data of each patient to construct personalised
gene networks. However, they require the genetic data of a pair of samples
(i.e. a tumour and its tumour neighbour), but identifying the neighbour of
a tumour is challenging and it is not always existing. In addition, these
methods only discover coding cancer drivers while non-coding genes (e.g.
miRNAs) can also be cancer drivers as discussed above.
3 Resources for cancer driver research
There are two types of resources for developing computational methods
for cancer driver discovery, including input data to a method and resource
for validation. As input, it can be gene expression data, network data,
mutation data, etc. For validation, it can be a database with ground truth
or partial ground truth. The resources are summarised in Table 2.
For input data, several databases have been developed from cancer
sequencing projects and they provide rich data used in cancer driver
identification methods. TCGA (Institute, 2018) is a significant project
in this area. The TCGA project profiles and analyses human tumours to
uncover molecular aberrations in DNA, XRNA, protein, and epigenetic
levels (Institute, 2018). TCGA data can be accessed through the Genomic
Data Commons (GDC) data portal (Grossman et al., 2016). ICGC data
portal is also a resource for cancer genomics data and it contains the data
of genomic abnormalities of 50 cancer types (Zhang et al., 2011). Another
data portal for cancer genomics is cBioPortal (Gao et al., 2013), which
provides a web interface for accessing cancer genomic datasets, as well as
for analysing and visualising the data online.
There are also some other resources which can be used for cancer driver
discovery such as the Cancer3D (Porta-Pardo et al., 2015), the Cancer Cell
Line Encyclopedia (CCLE) (Barretina et al., 2012), and the COSMIC
database (Forbes et al., 2015). Cancer3D is a database which focuses on
the influence of mutations on the structure of proteins and it provides
the information for users to analyse distribution patterns of mutations and
their relationship with changes in drug activity (Porta-Pardo et al., 2015). It
contains mutations of more than 14,700 proteins, which are mapped to over
24,300 proteins in the Protein Data Bank (Rose et al., 2013). The CCLE
includes SNVs, CNAs, and gene expression (Barretina et al., 2012). The
COSMIC database is a large and comprehensive source for investigating
the mutational impact in cancer. It contains records of cancer mutations
including both manually curated expert data and data from sequencing
projects like TCGA or ICGC (Forbes et al., 2015, 2011). It has more
than two million coding point mutations and over six million non-coding
mutations (Forbes et al., 2015).
For validating identified cancer drivers, several databases can be used
currently like CGC (Futreal et al., 2004) in the COSMIC database. The
CGC provides a gene list which has been well established for cancer
progression. This list was collected through a census of genes which
are mutated or implicated causally in cancer progression (Futreal et al.,
2004). These genes are also called cancer genes. Beside CGC in COSMIC,
there are several sources which can be used for validating cancer drivers.
The Atlas of Genetics and Cytogenetics in Oncology and Haematology
(AGCOH) is another source for this purpose (Huret et al., 2000). It
comprises around 1,500 cancer genes which are merged results from
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numerous collaborative projects (Huret et al., 2000). The Network of
Cancer Genes (NCG) is an online database of cancer genes with over
500 known cancer genes and more than 1,000 candidate cancer genes An
et al. (2016). Known cancer genes are genes which have already been
confirmed through experiments while candidate cancer genes are those
using statistical methods. One more database about disease genes is the
Drug-Gene Interaction database (DGIdb) (Griffith et al., 2013). It contains
not only cancer drivers but also the information about drugs and drug-gene
interactions (Griffith et al., 2013).
At the present, while coding drivers are well established in cancer
research, non-coding drivers are not. In (Wong et al., 2018), the authors
have recently introduced OncomiR, which is a resource for investigating
miRNA dysregulation in cancer through a web interface. It does statistical
analyses based on RNA-seq, miRNA-seq, and clinical information from
TCGA to discover miRNAs which are related to cancer progression.
Although this database may not be used as a ground truth to validate
miRNA cancer drivers, it can be used as a channel to explore miRNA
dysregulation in detecting miRNA cancer drivers. To validate non-coding
cancer drivers now, it is required to examine the literature manually
(Cuykendall et al., 2017; Poulos et al., 2015).
4 Comparative study
4.1 Performance of methods in identifying cancer drivers
In this section, we present a comparative study to compare the performance
of some methods above. As there is not a ground truth to compare the
results of methods for discovering cancer driver modules, we only select
five methods for identifying single cancer drivers and three methods for
identifying personalised cancer drivers for the comparison, including
ActiveDriver (Reimand and Bader, 2013), DawnRank (Hou and Ma,
2014), DriverML (Han et al., 2019), DriverNet (Bashashati et al., 2012),
MutSigCV (Lawrence et al., 2013), OncodriveFM (Gonzalez-Perez and
Lopez-Bigas, 2012), PNC (Guo et al., 2019), and SCS (Guo et al., 2018).
These methods represent for different approaches in detecting cancer
driver genes. ActiveDriver, DriverML, MutSigCV, and OncodriveFM are
mutation-based methods while DawnRank, DriverNet, PNC, and SCS are
network-based methods. In addition, DawnRank, PNC, and SCS identify
personalised cancer drivers while other five methods identify cancer drivers
at the population level. Although DawnRank, PNC, and SCS detect cancer
drivers for each patient, they all have a method to aggregate the results
of individual patients to predict cancer drivers for the population. Thus,
we can compare these three methods with the others. The comparison is
performed based on the results of the eight methods in identifying drivers
for breast invasive carcinoma (BRCA), lung adenocarcinoma (LUAD),
lung squamous cell carcinoma (LUSC), kidney renal clear cell carcinoma
(KIRC), head and neck squamous cell carcinoma (HNSC). We obtain the
predicted cancer drivers of the eight methods for the selected five cancer
types from (Guo et al., 2019).
The cancer drivers predicted by the methods are validated with the CGC
from the COSMIC database as this database has catalogued the confirmed
cancer drivers. The performance of a method is measured using F1Score
based on the number of discovered cancer drivers that are validated by the
CGC. The F1Score indicates the enrichment ability of discovered cancer
drivers in the gold standard (i.e. the CGC) and it is computed based on
Precision P and Recall R as shown in Eq. 1. The higher the F1Score a
method has, the better the method is.
F1Score = 2 ∗ P ∗R
P +R
. (1)
In Eq. 1, P (Precision) shows the fraction of predicted driver genes in
the CGC among the predicted driver genes and R (Recall) indicates the
fraction of predicted driver genes in the CGC among the driver genes in
the CGC. AsF1Score is computed from PrecisionP and RecallR, it will
indicate both the ability to predict exactly cancer drivers and the ability to
predict many confirmed cancer drivers of a method.
The comparison result is shown in Figure 4 and the details are shown
in Table 3. It can be seen that with the four data sets of BRCA, LUAD,
LUSC, and KIRC samples, PNC outperforms the other methods and with
HNSC, ActiveDriver has the best performance.
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Fig. 4. Comparison of F1Score of ActiveDriver, DawnRank, DriverML, DriverNet,
MutSigCV, OncodriveFM, PNC, and SCS in identifying coding cancer drivers at the
population level. The x-axis indicates the eight methods and the y-axis shows theF1Score.
The results are based on the cancer driver prediction for the five cancer types, including
BRCA, LUAD, LUSC, KIRC, and HNSC, of the eight methods.
Table 3. F1Score of the eight methods in predicting drivers for
the five cancer types
No. Method BRCA LUAD LUSC KIRC HNSC
1 ActiveDriver 0.056 0.029 0.037 0.045 0.080
2 DawnRank 0.045 0.043 0.040 0.040 0.043
3 DriverML 0.077 0.027 0.016 0.052 0.005
4 DriverNet 0.007 0.009 0.013 0.025 0.002
5 MutSigCV 0.066 0.032 0.014 0.016 0.034
6 OncodriveFM 0.023 0.030 0.010 0.015 0.045
7 PNC 0.153 0.153 0.141 0.094 0.025
8 SCS NA 0.011 0.005 0.008 NA
Moreover, to see if the methods detect similar cancer drivers, we
compare the results of the five methods used for identifying cancer
drivers at the population level (i.e. DriverML, ActiveDriver, DriverNet,
MutSigCV, and OncodriveFM). Figure 5 shows the overlap between the
validated cancer drivers discovered by each pair of the methods, for each
of the five cancer types. It can be seen that there is little overlap among
the results of the methods. For example, in breast cancer, only one cancer
driver (TP53) is identified by all the five methods, two cancer drivers
(CDH1 andPIK3CA) are detected by four methods (DriverML, DriverNet,
MutSigCV, and OncodriveFM), and eight cancer drivers (GATA3, NCOR1,
PTEN, ARID1A, FOXA1, PIK3R1, CTCF, and ERBB2) are predicted
by three methods. As the results of these methods are complementary,
they should be used together to maximize the overall performance of the
cancer driver prediction. In addition, it should be pointed out that although
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the CGC is popular in validating cancer drivers in cancer research, it is
incomplete in the sense that the database is constantly being updated when
new cancer drivers come to light. Therefore, although some of the predicted
cancer drivers cannot be validated with existing knowledge, they can be
novel cancer drivers which is worth wet-lab experiments to confirm their
roles in progressing cancer.
4.2 Identified cancer drivers enriched significantly in GO
biological processes and KEGG pathways
Taking breast cancer as an example, we combine all the breast cancer
drivers predicted by the five methods at the population level (i.e. DriverML,
ActiveDriver, DriverNet, MutSigCV, and OncodriveFM), which results in
altogether 509 cancer drivers. Among them, 63 drivers are predicted by at
least two of the five methods. We use Enrichr (Kuleshov et al., 2016) to do
enrichment analysis of these 63 drivers. Table 4 and Table 5 show the GO
biological processes and KEGG pathways in which these cancer drivers
are significantly enriched (adjusted p-value < 0.05). Among the 63 driver
genes, 16 genes (25.4%) are enriched in 7 GO biological processes and 15
genes (23.8%) are enriched in 26 KEGG pathways related to breast cancer.
It indicates that the predicted cancer drivers are closely associated with the
biological condition of breast cancer and biologically meaningful.
Table 4. GO biological processes involved in breast cancer in which the predicted
cancer drivers are enriched
Term #Genes p-value
GO:0045598 regulation of fat cell differentiation 5 2.0e-03
GO:0045596 negative regulation of cell differentiation 6 3.6e-03
GO:0045604 regulation of epidermal cell differentiation 3 1.2e-02
GO:0042127 regulation of cell proliferation 10 2.5e-02
GO:0045599 negative regulation of fat cell differentiation 3 2.8e-02
GO:0045580 regulation of T cell differentiation 3 2.9e-02
GO:2000736 regulation of stem cell differentiation 4 3.1e-02
4.3 Identified cancer drivers are useful in predicting
survival
Since the predicted cancer driver genes likely cause carcinogenesis, they
could be used as biomarkers to classify tumours. To explore this concept,
we use the predicted drivers to stratify breast cancer patients. Among the
63 predicted cancer drivers above, there are four significant genes, AKT1,
PTEN, CDKN1B, and TP53, which are enriched in both GO biological
processes and KEGG pathways. For instance, AKT1 are enriched in two
GO biological processes and 25 KEGG pathways, PTEN are enriched
in two GO biological processes and five KEGG pathways. Thus, we
use these four genes for this analysis. In addition, we obtain the BRCA
gene expression data and clinical data from (Zhang et al., 2019), and
use the Similarity Network Fusion (SNF) method (Wang et al., 2014; Xu
et al., 2017b), a popular method for discovering the similarities among
patients, to cluster cancer patients. The SNF takes expression of these
four genes as input and outputs subtypes of cancer patients. We then
analyse the survival outcomes of patients in the classified subtypes. The
results indicate that the survival level of patients in different classified
subtypes are significantly different (p-value = 0.0245) as shown in Figure 6.
Furthermore, the clustering display shows the similarity of samples in each
identified subtype and the silhouette plot indicates a good clustering with
a large average silhouette width (0.76).
Table 5. KEGG pathways involved in breast cancer in which the predicted cancer
drivers are enriched
Term #Genes p-value
ErbB signaling pathway 6 5.3e-06
Thyroid hormone signaling pathway 6 2.8e-05
Sphingolipid signaling pathway 6 3.1e-05
Neurotrophin signaling pathway 6 3.0e-05
PI3K-Akt signaling pathway 8 1.7e-04
AGE-RAGE signaling pathway in diabetic complications 5 1.7e-04
HIF-1 signaling pathway 5 1.7e-04
FoxO signaling pathway 5 5.1e-04
Fc epsilon RI signaling pathway 4 5.2e-04
Toll-like receptor signaling pathway 4 2.2e-03
TNF signaling pathway 4 2.7e-03
Relaxin signaling pathway 4 4.6e-03
VEGF signaling pathway 3 5.1e-03
Estrogen signaling pathway 4 5.3e-03
mTOR signaling pathway 4 7.3e-03
Prolactin signaling pathway 3 7.4e-03
B cell receptor signaling pathway 3 7.6e-03
p53 signaling pathway 3 7.8e-03
MAPK signaling pathway 5 1.2e-02
T cell receptor signaling pathway 3 1.8e-02
Rap1 signaling pathway 4 1.8e-02
C-type lectin receptor signaling pathway 3 1.9e-02
AMPK signaling pathway 3 2.6e-02
Apelin signaling pathway 3 3.5e-02
Insulin signaling pathway 3 3.4e-02
Phospholipase D signaling pathway 3 4.1e-02
5 Gaps and future directions
From the discussion above, we see that there are a wide range of
computational methods for identifying cancer drivers from genomic data.
In this paper, we categorise the methods into three groups: methods for
identifying single cancer drivers (including mutation-based methods and
network-based methods), methods for identifying cancer driver modules,
and methods for identifying personalised cancer drivers. Although these
methods have detected successfully various cancer drivers, there are still
several gaps in the research of the field.
Firstly, most of the current methods focus on coding mutations to
identify coding cancer drivers while non-coding cancer drivers are not fully
examined and the number of methods for identifying non-coding drivers
is limited. However, non-coding cancer drivers are important because
protein-coding regions account for only around two percent of the human
genome. The large part of mutations exist in non-coding regions and these
mutations can regulate the expression of genes and drive cancer (Puente
et al., 2015; Weinhold et al., 2014). In addition to the limited number
of non-coding cancer driver identification methods, the current methods
focus much on non-coding mutations, i.e., correlations of mutations in non-
coding elements with other factors like survival (Hornshoj et al., 2018).
Nevertheless, cancer drivers can be non-coding RNAs without mutations
but they can regulate other genes to progress cancer, thus it is required
to investigate non-coding RNAs with and without mutations to detect
non-coding cancer drivers.
Secondly, some methods have been developed to identify groups of
cancer drivers (Ciriello et al., 2012; Zhang et al., 2013), but they are
mostly based on mutations to detect mutated modules, called cancer driver
modules. Since in a module, the mutation of a member is sufficient
to develop cancer, the identified drivers in a module may not in fact
work together to regulate their targets to drive cancer. However, there
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Fig. 5. Overlap among the cancer drivers predicted by different methods. The charts illustrate the overlap among the cancer drivers at the population level predicted by the five methods
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cancer subtypes identified by using the four predicted cancer drivers, including AKT1,
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survivals of patients of the two subtypes (p-value = 0.0245). The clustering display indicates
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show the similarity of samples). The silhouette plot has a large average silhouette width
(0.76/1), indicating the clustering validity when using these four genes.
is evidence that some genes work in concert to regulate other genes’
expression and influence different biological processes, such as the
cooperation of miRNAs in EMT, the transformation of epithelial cells
into mesenchymal cells (Cursons et al., 2017; Lamouille et al., 2014).
In addition, in some biological processes, the regulation of single genes
might not have significant impacts and research has emerged to use wet-
lab experiments to investigate the regulatory of group-based regulators in
biological processes. All of these highlight the importance of studying
biological factors in groups, and computational methods which utilise a
variety of data and techniques are in demand for investigating groups of
cancer drivers.
Finally, although there have been methods for detecting personalised
cancer drivers (Guo et al., 2018, 2019; Hou and Ma, 2014), they still
have some limitations. Some methods, such as DawnRank, use the gene
network of the population to predict personlaised cancer drivers. This
leads to that they may ignore the information of the gene network specific
to an individual patient and they may discover many false positives in their
results. Other methods, such as SCS and PNC, use the personal genetic
data to build personalised gene networks but they need the genetic data
of a sample pair (i.e. a cancer patient and its neighbour in the nomal
state). The neighbour of a cancer patient is not always existing. Thus,
the application of these methods is limited. Furthermore, these methods
only detect coding cancer drivers while it is also necessary to identify
non-coding cancer drivers as the discussion above. All of these indicate
that there is a strong need to develop novel computational methods for
detecting personalised coding/non-coding cancer drivers.
6 Recommendation and conclusion
We have investigated a wide range of computational methods for
identifying cancer drivers from genomic data. In addition, the advantages
and limitations of the surveyed methods are analysed, based on which
we identify various opportunities for the development of the research in
the field. It is clear that the research in computational approach to cancer
driver identification is still in its growth phase. Much more work needs
to be done and many opportunities exist in this area. Nevertheless, there
are also different challenges in advancing the research in cancer driver
identification. Identifying exactly biological factors which drive cancer
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is quite complicated. Future research needs to focus on both coding and
non-coding datasets to identify candidate cancer drivers. To improve the
accuracy of the novel computational methods, we should combine different
types of data such as gene expression, mutations, and clinical information,
etc. to detect cancer drivers.
We have also surveyed available resources which can be used in the
research of discovering cancer drivers. The existing resources are plentiful
but they are fragmented. Thus, to utilise cancer data more effectively for
the research, it requires to have policies to achieve better data sharing. In
addition, another difficulty when developing computational methods for
uncovering non-coding cancer drivers is the validation. The reason is that
most of the current databases are for coding cancer drivers and there is no
one for non-coding cancer drivers. Therefore, we make an urgent call for
the building of databases for non-coding drivers given their crucial role in
the success of the research in the field.
To evaluate the performance of some current methods in detecting
cancer drivers as well as provide an example of the evaluation of cancer
driver discovery methods for the researchers who would like to penetrate
the field, a comparative study has been conducted. From the results of
the experiment in the comparative study, it can be seen that each method
can uncover different cancer drivers and the overlaps between the results
of the methods are small. Therefore, the methods are complementary,
and we should use them together to maximize the effectiveness of cancer
driver prediction of the methods. This is also an indicator for the different
approaches of the methods and to achieve a significant result, novel
methods should combine various resources and techniques in detecting
cancer drivers.
In conclusion, although there are numerous computational methods for
discovering cancer drivers now, there exist various gaps and opportunities
for advancing the research of the field. However, due to the complexity
of cancer initialisation and development, identifying cancer drivers faces
many challenges. Through this paper, we hope that we can help researchers
who are interested in the filed to establish a solid background and motivate
them to tackle the current challenges.
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